Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immnoconjugate Therapy in Patients with B-Cell Non-Hodgkin Lymphoma

Authors

Aliza Gardenswartz, New York Medical College
Karen Seiter, New York Medical CollegeFollow
J Hochberg, New York Medical College
E Morris
L Harrison
Yaya Chu, New York Medical CollegeFollow
J Basso
P Gerard, New York Medical College
H Islam, New York Medical College
Janet Ayello, New York Medical CollegeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

10-2022

Journal Title

Leukemia Research

Department

Medicine

Second Department

Pediatrics

Third Department

Radiology

Recommended Citation

Gardenswartz, A., Seiter, K., Hochberg, J., Morris, E., Harrison, L., Chu, Y., Basso, J., Gerard, P., Islam, H., Ayello, J., & Cairo, M. S. (2022). Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immnoconjugate Therapy in Patients with B-Cell Non-Hodgkin Lymphoma. Leukemia Research, 121 (Suppl.), S24-S25. https://doi.org/10.1016/S0145-2126(22)00227-2